Timing of HPV16-E6 antibody seroconversion before OPSCC : findings from the HPVC3 consortium

Show full item record



Permalink

http://hdl.handle.net/10138/306982

Citation

Kreimer , A R , Ferreiro-Iglesias , A , Nygard , M , Bender , N , Schroeder , L , Hildesheim , A , Robbins , H A , Pawlita , M , Langseth , H , Schlecht , N F , Tinker , L F , Agalliu , Smoller , S W , Ness-Jensen , E , Hveem , K , D'Souza , G , Visvanathan , K , May , B , Ursin , G , Weiderpass , E , Giles , G G , Milne , R L , Cai , Q , Blot , W J , Zheng , W , Weinstein , S J , Albanes , D , Brenner , N , Hoffman-Bolton , J , Kaaks , R , Barricarte , A , Tjonneland , A , Sacerdote , C , Trichopoulou , A , Vermeulen , R C H , Huang , W-Y , Freedman , N D , Brennan , P , Waterboer , T & Johansson , M 2019 , ' Timing of HPV16-E6 antibody seroconversion before OPSCC : findings from the HPVC3 consortium ' , Annals of Oncology , vol. 30 , no. 8 , pp. 1335-1343 . https://doi.org/10.1093/annonc/mdz138

Title: Timing of HPV16-E6 antibody seroconversion before OPSCC : findings from the HPVC3 consortium
Author: Kreimer, A. R.; Ferreiro-Iglesias, A.; Nygard, M.; Bender, N.; Schroeder, L.; Hildesheim, A.; Robbins, H. A.; Pawlita, M.; Langseth, H.; Schlecht, N. F.; Tinker, L. F.; Agalliu,; Smoller, S. W.; Ness-Jensen, E.; Hveem, K.; D'Souza, G.; Visvanathan, K.; May, B.; Ursin, G.; Weiderpass, E.; Giles, G. G.; Milne, R. L.; Cai, Q.; Blot, W. J.; Zheng, W.; Weinstein, S. J.; Albanes, D.; Brenner, N.; Hoffman-Bolton, J.; Kaaks, R.; Barricarte, A.; Tjonneland, A.; Sacerdote, C.; Trichopoulou, A.; Vermeulen, R. C. H.; Huang, W-Y; Freedman, N. D.; Brennan, P.; Waterboer, T.; Johansson, M.
Contributor: University of Helsinki, Department of Medical and Clinical Genetics
Date: 2019-08
Language: eng
Number of pages: 9
Belongs to series: Annals of Oncology
ISSN: 0923-7534
URI: http://hdl.handle.net/10138/306982
Abstract: Background: Human papillomavirus type 16 (HPV16)-E6 antibodies are detectable in peripheral blood before diagnosis in the majority of HPV16-driven oropharyngeal squamous cell carcinoma (OPSCC), but the timing of seroconversion is unknown. Patients and methods: We formed the HPV Cancer Cohort Consortium which comprises nine population cohorts from Europe, North America and Australia. In total, 743 incident OPSCC cases and 5814 controls provided at least one pre-diagnostic blood sample, including 111 cases with multiple samples. Median time between first blood collection and OPSCC diagnosis was 11.4 years (IQR = 6-11 years, range = 0-40 years). Antibodies against HPV16-E6 were measured by multiplex serology (GST fusion protein based Luminex assay). Results: HPV16-E6 seropositivity was present in 0.4% of controls (22/5814; 95% CI 0.2% to 0.6%) and 26.2% (195/743; 95% CI 23.1% to 29.6%) of OPSCC cases. HPV16-E6 seropositivity increased the odds of OPSCC 98.2-fold (95% CI 62.1-155.4) in whites and 17.2-fold (95% CI 1.7-170.5) in blacks. Seropositivity in cases was more frequent in recent calendar periods, ranging from 21.9% pre-1996 to 68.4% in 2005 onwards, in those with blood collection near diagnosis (lead time 30 years (N = 24), 20-30 years (N = 148), 10-20 years (N = 228), and Conclusions: The immune response to HPV16-driven tumorigenesis is most often detectable several decades before OPSCC diagnosis. HPV16-E6 seropositive individuals face increased risk of OPSCC over several decades.
Subject: HPVC3
OPCSCC
oropharyngeal squamous cell carcinoma
HUMAN-PAPILLOMAVIRUS
HEAD
CANCER
DESIGN
COHORT
RISK
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
mdz138.pdf 417.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record